Effects of selective dopamine-1 receptor activation on intraocular pressure in man
- PMID: 2904373
- DOI: 10.1016/0014-4835(88)90036-x
Effects of selective dopamine-1 receptor activation on intraocular pressure in man
Abstract
The lack of specific agonists and antagonists has, until recently, precluded investigation of a role for dopamine receptors in the control of intraocular pressure. In the present study, we have examined the effects of fenoldopam, a novel selective dopamine1 (DA1) receptor agonist, on intraocular pressure, in eight healthy human volunteers. Fenoldopam, infused intravenously at 0.5 micrograms kg-1 min-1, increased intraocular pressure from 14.6 +/- 0.9 to 17.6 +/- 1.4 mmHg (P less than 0.05) while a control saline infusion had no effect. Pupil diameter and blood pressure did not change. In the same subjects, i.v. norepinephrine or angiotensin II both increased intraocular pressure--from 13.8 +/- 1.4- to 17.6 +/- 1.4 mmHg and from 13.4 +/- 1.3- to 17.5 +/- 1.7 mmHg respectively (P less than 0.05), and mean arterial pressure by about 20 mmHg. These data suggest that: (1) DA1 receptor activation can modulate intraocular pressure; (2) the intraocular pressure effects of the DA1 receptor agonist, fenoldopam, are independent of changes in systemic blood pressure, in contrast to those of norepinephrine or angiotensin II where intraocular and systemic blood pressures increase in parallel; (3) the ability of a DA1 receptor antagonist to lower intraocular pressure merits investigation.
Similar articles
-
Effects of dopamine DA1-receptor blockade and angiotensin converting enzyme inhibition on the renal actions of fenoldopam in the anaesthetized dog.J Hypertens. 1991 Dec;9(12):1143-50. J Hypertens. 1991. PMID: 1685741
-
Relative DA1-dopamine-receptor agonist and alpha-adrenoceptor antagonist activity of fenoldopam in the anesthetized dog.J Cardiovasc Pharmacol. 1988 Jan;11(1):123-6. doi: 10.1097/00005344-198801000-00018. J Cardiovasc Pharmacol. 1988. PMID: 2450250
-
Activation of DA1 receptors by dopamine or fenoldopam increases cyclic AMP levels in the renal artery but not in the superior cervical ganglion of the rat.J Pharmacol Exp Ther. 1986 Aug;238(2):547-53. J Pharmacol Exp Ther. 1986. PMID: 2874213
-
The pharmacology of fenoldopam.Am J Hypertens. 1990 Jun;3(6 Pt 2):116S-119S. doi: 10.1093/ajh/3.6.116s. Am J Hypertens. 1990. PMID: 1974439 Review.
-
Dopamine receptors and hypertension. Physiologic and pharmacologic implications.Am J Med. 1984 Oct 5;77(4A):37-44. doi: 10.1016/s0002-9343(84)80036-4. Am J Med. 1984. PMID: 6148892 Review.
Cited by
-
Determination of dopamine D1 receptors in the human uveo scleral tissue by light microscope autoradiography.Int Ophthalmol. 1999;23(3):171-9. doi: 10.1023/a:1010611419602. Int Ophthalmol. 1999. PMID: 11456256
-
Role of dopaminergic receptors in glaucomatous disease modulation.Biomed Res Int. 2013;2013:193048. doi: 10.1155/2013/193048. Epub 2013 Jun 26. Biomed Res Int. 2013. PMID: 23878797 Free PMC article. Review.
-
Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies.Drugs. 1997 Oct;54(4):634-50. doi: 10.2165/00003495-199754040-00008. Drugs. 1997. PMID: 9339965 Review.
-
Direct demonstration of dopamine D1-like receptor sites in the ciliary body of the rabbit eye by light microscope autoradiography.Naunyn Schmiedebergs Arch Pharmacol. 1992 Dec;346(6):644-8. doi: 10.1007/BF00168737. Naunyn Schmiedebergs Arch Pharmacol. 1992. PMID: 1362453
-
Ocular hypotensive effect of topical ketanserin in timolol users.Graefes Arch Clin Exp Ophthalmol. 1997 Mar;235(3):130-5. doi: 10.1007/BF00941719. Graefes Arch Clin Exp Ophthalmol. 1997. PMID: 9085107 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Miscellaneous